The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
Official Title: A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma
Study ID: NCT00761722
Brief Summary: The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
California Cancer Care Inc, Greenbrae, California, United States
Main Cancer Centers of Florida, P.A., Ocoee, Florida, United States
Indiana University School of Medicine, Indianapolis, Indiana, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Northwest Cancer Specialists, P.C., Albuquerque, New Mexico, United States
Willamette Valley Cancer Institute, Springfield, Oregon, United States
University of Texas- MD Anderson, Houston, Texas, United States
Hematology and Oncology Assoc. of South Texas, San Antonio, Texas, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States
Name: Barry Skikne, MD, FACP, FCP (SA)
Affiliation: Celgene Corporation
Role: STUDY_DIRECTOR